LB Pharmaceuticals Inc
NASDAQ:LBRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
LB Pharmaceuticals Inc
NASDAQ:LBRX
|
US |
|
Sigma Solve Ltd
NSE:SIGMA
|
IN |
|
H
|
HALEON PLC
OTC:HLNCF
|
UK |
LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York. The company went IPO on 2025-09-11. LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
LB Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York. The company went IPO on 2025-09-11. LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
